TALLEVAST-- Rock Creek Pharmaceuticals Inc., a drug development company focused on chronic inflammatory disease and neurologic disorders, announced that abstracts outlining four preclinical studies evaluating anatabine have been accepted for poster and symposium presentations at the upcoming annual meeting of the Society for Neuroscience.
"The data from the accepted abstracts demonstrates the continued application of anatabine for beneficial effects in preclinical mouse models of human diseases," said Michael J. Mullan, Ph.D., Rock Creek Pharmaceuticals' Chairman and CEO..
The symposium takes place Nov. 15-19 in Washington, D.C. This meeting is the premiere event in the field, typically attracting 30,000 attendees, with 15,000 scientific presentations and nearly 600 presenting companies.
Anatabine is an investigatory drug that was included in Anatabloc, which the company pulled from the shelves this summer. The drug was also at the center of a corruption trial of the former Virgina Gov. Bob McDonnell and his wife Maureen McDonnell.
The studies were independently conducted by Manatee County-based Roskamp Institute, a not-for-profit research organization devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addiction. The studies were funded by either the Roskamp Foundation or by awards through the Congressionally Directed Medical Research Program.